Seeking Alpha

Impax Laboratories (IPXL) settles a lawsuit with Sanofi (SNY) unit Genzyme over two kidney...

Impax Laboratories (IPXL) settles a lawsuit with Sanofi (SNY) unit Genzyme over two kidney disease drugs, with the latter agreeing to grant Impax a license to sell generic versions of Renvela and Renagel by mid-March 2014 and mid-September 2014 respectively. Last month Impax settled with Pfizer over bladder control treatment Detrol LA. (PR)
From other sites
Comments (1)
  • Scrying Biotech
    , contributor
    Comments (2123) | Send Message
    I like this! Impax looks long-term. Word on the Street was that Impax would take a cash settlement projected to be anywhere between $100M and $1B on this suit. Instead, Impax chose to postpone gratification accepting an offer to produce generic versions of Renagel and Renvela in 2014. Both of these drugs had net sales of $392M in the FIRST HALF of 2012. Now I don't know the viability projections for those drugs in 2014 and beyond but I'll bet Impax does and it's safe to say that Impax hit a grand slam home run here that certainly grows revenues for another 5 - 10 years.


    Additionally, it says that Impax present revenue growth is strong and will be projected to be so into 2014. **** Impax Labs ****
    5 Sep 2012, 03:42 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs